Aarti Drugs Ltd

Aarti Drugs Limited: Trading Window closed from October 1, 2026 until the expiry of 48 hours after the declaration of Financial Results for the quarter and half year ended September 30, 2026.

Director and KMP changes

• Ceased: Shri Uday M. Patil, Whole-time Director, at AGM on Sept 26, 2026, due to retirement by rotation.
• Appointed: Shri Nilesh Bhalchandra Patil as Director and Whole-time Director; profile: B.Com, MBA, 33 years with Company.
• Appointed: Adhish Prakash Patil as Director; profile: 21 years in manufacturing, finance; BE IT, MBA from Warrington, Florida.
• Appointed: Adhish Prakash Patil as Managing Director; profile: 21 years in leadership; BE IT, MBA from Warrington.
• Re-appointment: Harshit M. Savla as Joint Managing Director for five years from June 01, 2027.
• Re-appointment: Harit Pragji Shah as Whole-time Director for five years from June 01, 2027.
• Re-appointment: Hasmukh Bhavanji Dedhia as Independent Director for second term of five years from March 29, 2027.
• Re-appointment: Sandeep Madhusudan Joshi as Independent Director for second term of five years from March 29, 2027.
• Re-appointment: Ajit Eledath Venugopalan as Independent Director for second term of three years from March 29, 2027.
• Relationship: Adhish Prakash Patil is son of Chairman Prakash M. Patil.

AGM Details

• AGM held on 26 September 2026 at 11:00 IST via VC/OAVM
• Record date: 19 September 2026; shareholders on record: 143,365
• Remote e-voting: 23–25 September 2026; unblocked 26 September 2026

Key Resolutions & Outcomes

• Resolution 1 (Ordinary): Adopt standalone and consolidated financial statements; Passed
• Resolution 2 (Ordinary): Rotation retirement of U M Patil; not reappointed; Passed
• Resolution 3 (Ordinary): Nilesh Patil appointed as Director; Passed
• Resolution 4 (Ordinary): Nilesh Patil appointed as Whole-time Director; Passed
• Resolution 5 (Ordinary): Adhish Patil appointed as Director; Passed
• Resolution 6 (Ordinary): Adhish Patil appointed as Managing Director; Passed
• Resolution 7 (Ordinary): Harshit Savla reappointed as Joint Managing Director; Passed
• Resolution 8 (Ordinary): Harit Shah reappointed as Whole-time Director; Passed
• Resolution 9 (Special): Hasmukh Dedhia reappointed as Independent Director (second term); Passed
• Resolution 10 (Special): Sandeep Joshi reappointed as Independent Director (second term); Passed
• Resolution 11 (Special): Ajit Venugopalan reappointed as Independent Director (second term); Passed
• Resolution 12 (Ordinary): Related party Prakash Moreshwar Patil to hold office of profit; Passed
• Resolution 13 (Special): Profit-related Commission to non-executive directors; Passed
• Resolution 14 (Special): PSOP 2026 approved; For about 84.79%
• Resolution 15 (Special): PSOP 2026 grant to subsidiaries' employees; For about 84.79%
• Resolution 16 (Ordinary): Cost Auditors remuneration ratified for FY2026-27; Passed

Director Changes

• Uday M. Patil retires by rotation; not reappointed
• Nilesh Bhalchandra Patil appointed Director
• Nilesh Bhalchandra Patil appointed Whole-time Director
• Adhish Prakash Patil appointed Director
• Adhish Prakash Patil appointed Managing Director
• Harshit Manilal Savla reappointed as Joint Managing Director
• Harit Pragji Shah reappointed as Whole-time Director
• Hasmukh Bhavanji Dedhia reappointed Independent Director (second term)
• Sandeep Madhusudan Joshi reappointed Independent Director (second term)
• Ajit Eledath Venugopalan reappointed Independent Director (second term)

Auditors

• Remuneration of Cost Auditors ratified for FY2026-27

Material Related Party Transactions

• Related Party Prakash Moreshwar Patil approved to hold office of profit
• Profit Related Commission payable to non-executive directors approved

Other material approvals

• PSOP 2026 approved
• Stock options under PSOP 2026 granted to employees of subsidiaries/group/associate companies

Operational & Growth Highlights

• Capacity expansion via Sayakha and Tarapur lifts capacity to 82,512 MT in 2025-26.
• USFDA, UK-MHRA, EU-GMP approvals obtained for oncology OSD facilities.
• ₹200 crore invested over 24 months for oncology development and pipeline growth.
• Regulated-market push with 330 regulatory filings across 16 geographies; Latin America launches.
• Regulated markets focus with EDQM approvals; oncology expansion into complex generics.

AGM Details

• Date, time and mode: 26 September 2026, 11:00 AM, via Video Conferencing & OAVM.
• Quorum: 93 members attended via VC.
• Record date for voting rights: 19 September 2026 cut-off.
• Remote e-voting window: 23 Sept 2026 9:00 AM to 25 Sept 2026 5:00 PM.
• AGM concluded at 11:57 AM; 30-minute post-meeting e-voting window.

Resolutions

• Res 1 (Ord): Adoption of standalone and consolidated financial statements; outcome to be announced.
• Res 2 (Ord): Retirement by rotation of Shri Uday M. Patil; not re-appointed.
• Res 3 (SP): Appointment of Shri Nilesh Bhalchandra Patil as Director.
• Res 4 (SP): Appointment of Shri Nilesh Bhalchandra Patil as Whole-time Director.
• Res 5 (SP): Appointment of Shri Adhish Prakash Patil as Director.
• Res 6 (SP): Appointment of Shri Adhish Prakash Patil as Managing Director.
• Res 7 (SP): Re-appointment of Shri Harshit Manilal Savla as Joint Managing Director.
• Res 8 (SP): Re-appointment of Shri Harit Pragji Shah as Whole-time Director.
• Res 9 (SP): Re-appointment of Shri Hasmukh Bhavanji Dedhia as Independent Director for second term.
• Res 10 (SP): Re-appointment of Shri Sandeep Madhusudan Joshi as Independent Director for second term.
• Res 11 (SP): Re-appointment of Shri Ajit Eledath Venugopalan as Independent Director for second term.
• Res 12 (SP): Approval to Shri Prakash Moreshwar Patil to hold office or profit.
• Res 13 (SP): Profit-related Commission payable to Non-executive Directors.
• Res 14 (SP): Aarti Drugs Limited PSOP 2026 approved.
• Res 15 (SP): PSOP 2026 stock options to employees of subsidiaries/group/associates.
• Res 16 (SP): Ratification of remuneration of Cost Auditors for FY 2026-27.

Director Changes

• Appointment of Shri Nilesh Bhalchandra Patil as Director.
• Appointment of Shri Nilesh Bhalchandra Patil as Whole-time Director.
• Appointment of Shri Adhish Prakash Patil as Director.
• Appointment of Shri Adhish Prakash Patil as Managing Director.
• Re-appointment of Shri Harshit Manilal Savla as Joint Managing Director.
• Re-appointment of Shri Harit Pragji Shah as Whole-time Director.
• Re-appointment of Shri Hasmukh Bhavanji Dedhia as Independent Director for second term.
• Re-appointment of Shri Sandeep Madhusudan Joshi as Independent Director for second term.
• Re-appointment of Shri Ajit Eledath Venugopalan as Independent Director for second term.

Other Material Approvals

• Related party approval: Prakash Patil to hold office or profit.
• PSOP/ESOP approvals: PSOP 2026 for employees of group/subsidiaries.
• Cost Auditor remuneration: Ratified for FY 2026-27.

Voting Status

• Voting results to be declared within 2 working days after AGM.

BR&S report scope

• BR&S report for FY2025-26 submitted; standalone basis; available on company website.

Business activities & product mix

• API manufacturing dominates; API 89% turnover; speciality chemicals 8%; intermediates 3.

Governance & leadership

• Board 12; KMP 2; female director 1 (8.33%).

GHG emissions & energy intensity

• Scope 1: 134,907; Scope 2: 71,424 t; intensity 0.91 t per 1,00,000 turnover; 4.52 t/MT.

Water management

• Water withdrawal 683,217 KL; 10 of 12 API plants ZLD; CETP for 2 units.

Waste management

• Total waste 51,415 MT; hazardous waste 44,455 MT; co-processing 14,428 MT; incineration 3 MT; landfilling 5,844 MT.

CSR & social impact

• CSR beneficiaries include 15k education, 12k healthcare, 10k each across infrastructure, environment, housing, weaker sections, tribal/rural.

Human rights & supply chain governance

• Ethics Committee; Whistleblower policy; no HR violations; value-chain HR assessments ongoing.

Key highlights (FY2025-26)

• Consolidated revenue ₹2,568 crore, up ~7% YoY.
• EBITDA ₹312 crore.
• PAT ₹195 crore.
• Export revenue share 38%.
• Regulated markets share 73%.
• Formulations exports share 66%.
• Cash flow from operations ₹25,353.85 lakh.
• Interim dividend ₹2 per share.
• Sayakha methylamines facility commissioned Sep-2025; ~1,000 TPM by Mar-2026.
• PSOP 2026 approved; total options 8,00,000; vesting max 7 years.